vs
Side-by-side financial comparison of AbbVie (ABBV) and Enhabit, Inc. (EHAB). Click either name above to swap in a different company.
AbbVie is the larger business by last-quarter revenue ($16.6B vs $270.4M, roughly 61.5× Enhabit, Inc.). AbbVie runs the higher net margin — 10.9% vs -14.3%, a 25.2% gap on every dollar of revenue. On growth, AbbVie posted the faster year-over-year revenue change (10.0% vs 4.7%). AbbVie produced more free cash flow last quarter ($4.9B vs $3.3M). Over the past eight quarters, AbbVie's revenue compounded faster (16.2% CAGR vs 1.5%).
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. They have produced drugs to treat a wide range of medical issues.
Enhabit, Inc., is a Dallas, Texas-based provider of home health and hospice services. The company operates 255 home health and 110 hospice locations in 34 states with a concentration in Texas, Alabama, Florida, Georgia, Oklahoma and Mississippi. Enhabit is the fourth-largest provider of home health services in the United States and is a leading provider of hospice services. The company was formed in 2022 when Encompass Health spun off its home health and hospice business.
ABBV vs EHAB — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $16.6B | $270.4M |
| Net Profit | $1.8B | $-38.7M |
| Gross Margin | 72.6% | — |
| Operating Margin | 27.3% | -12.3% |
| Net Margin | 10.9% | -14.3% |
| Revenue YoY | 10.0% | 4.7% |
| Net Profit YoY | 8354.5% | 15.9% |
| EPS (diluted) | $1.02 | $-0.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.6B | $270.4M | ||
| Q3 25 | $15.8B | $263.6M | ||
| Q2 25 | $15.4B | $266.1M | ||
| Q1 25 | $13.3B | $259.9M | ||
| Q4 24 | $15.1B | $258.2M | ||
| Q3 24 | $14.5B | $253.6M | ||
| Q2 24 | $14.5B | $260.6M | ||
| Q1 24 | $12.3B | $262.4M |
| Q4 25 | $1.8B | $-38.7M | ||
| Q3 25 | $186.0M | $11.1M | ||
| Q2 25 | $938.0M | $5.2M | ||
| Q1 25 | $1.3B | $17.8M | ||
| Q4 24 | $-22.0M | $-46.0M | ||
| Q3 24 | $1.6B | $-110.2M | ||
| Q2 24 | $1.4B | $-200.0K | ||
| Q1 24 | $1.4B | $200.0K |
| Q4 25 | 72.6% | — | ||
| Q3 25 | 66.4% | — | ||
| Q2 25 | 71.8% | — | ||
| Q1 25 | 70.0% | — | ||
| Q4 24 | 70.9% | — | ||
| Q3 24 | 70.9% | — | ||
| Q2 24 | 70.9% | — | ||
| Q1 24 | 66.7% | — |
| Q4 25 | 27.3% | -12.3% | ||
| Q3 25 | 12.1% | 6.4% | ||
| Q2 25 | 31.7% | 6.3% | ||
| Q1 25 | 28.0% | 6.1% | ||
| Q4 24 | -9.9% | -16.0% | ||
| Q3 24 | 26.5% | -38.6% | ||
| Q2 24 | 27.6% | 4.3% | ||
| Q1 24 | 22.7% | 4.9% |
| Q4 25 | 10.9% | -14.3% | ||
| Q3 25 | 1.2% | 4.2% | ||
| Q2 25 | 6.1% | 2.0% | ||
| Q1 25 | 9.6% | 6.8% | ||
| Q4 24 | -0.1% | -17.8% | ||
| Q3 24 | 10.8% | -43.5% | ||
| Q2 24 | 9.5% | -0.1% | ||
| Q1 24 | 11.1% | 0.1% |
| Q4 25 | $1.02 | $-0.76 | ||
| Q3 25 | $0.10 | $0.22 | ||
| Q2 25 | $0.52 | $0.10 | ||
| Q1 25 | $0.72 | $0.35 | ||
| Q4 24 | $-0.03 | $-0.92 | ||
| Q3 24 | $0.88 | $-2.20 | ||
| Q2 24 | $0.77 | $0.00 | ||
| Q1 24 | $0.77 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.3B | $43.6M |
| Total DebtLower is stronger | $58.9B | $426.0M |
| Stockholders' EquityBook value | $-3.3B | $534.0M |
| Total Assets | $134.0B | $1.2B |
| Debt / EquityLower = less leverage | — | 0.80× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.3B | $43.6M | ||
| Q3 25 | $5.7B | $56.9M | ||
| Q2 25 | $6.5B | $37.1M | ||
| Q1 25 | $5.2B | $39.5M | ||
| Q4 24 | $5.6B | $28.4M | ||
| Q3 24 | $7.3B | $45.7M | ||
| Q2 24 | $13.2B | $28.5M | ||
| Q1 24 | $18.1B | $36.5M |
| Q4 25 | $58.9B | $426.0M | ||
| Q3 25 | $63.0B | $441.5M | ||
| Q2 25 | $63.0B | $456.9M | ||
| Q1 25 | $64.5B | $467.3M | ||
| Q4 24 | $60.3B | $492.6M | ||
| Q3 24 | $58.5B | $502.9M | ||
| Q2 24 | $58.0B | $512.7M | ||
| Q1 24 | $63.8B | $526.7M |
| Q4 25 | $-3.3B | $534.0M | ||
| Q3 25 | $-2.6B | $566.8M | ||
| Q2 25 | $-183.0M | $552.4M | ||
| Q1 25 | $1.4B | $543.2M | ||
| Q4 24 | $3.3B | $523.5M | ||
| Q3 24 | $6.0B | $566.1M | ||
| Q2 24 | $6.8B | $674.3M | ||
| Q1 24 | $8.0B | $672.3M |
| Q4 25 | $134.0B | $1.2B | ||
| Q3 25 | $133.9B | $1.2B | ||
| Q2 25 | $137.2B | $1.2B | ||
| Q1 25 | $136.2B | $1.2B | ||
| Q4 24 | $135.2B | $1.2B | ||
| Q3 24 | $143.4B | $1.3B | ||
| Q2 24 | $141.9B | $1.4B | ||
| Q1 24 | $148.9B | $1.4B |
| Q4 25 | — | 0.80× | ||
| Q3 25 | — | 0.78× | ||
| Q2 25 | — | 0.83× | ||
| Q1 25 | 45.44× | 0.86× | ||
| Q4 24 | 18.15× | 0.94× | ||
| Q3 24 | 9.70× | 0.89× | ||
| Q2 24 | 8.56× | 0.76× | ||
| Q1 24 | 7.97× | 0.78× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $5.2B | $4.4M |
| Free Cash FlowOCF − Capex | $4.9B | $3.3M |
| FCF MarginFCF / Revenue | 29.4% | 1.2% |
| Capex IntensityCapex / Revenue | 2.0% | 0.4% |
| Cash ConversionOCF / Net Profit | 2.87× | — |
| TTM Free Cash FlowTrailing 4 quarters | $17.8B | $65.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.2B | $4.4M | ||
| Q3 25 | $7.0B | $37.8M | ||
| Q2 25 | $5.2B | $10.6M | ||
| Q1 25 | $1.6B | $17.9M | ||
| Q4 24 | $7.0B | $-4.1M | ||
| Q3 24 | $5.4B | $28.4M | ||
| Q2 24 | $2.3B | $9.6M | ||
| Q1 24 | $4.0B | $17.3M |
| Q4 25 | $4.9B | $3.3M | ||
| Q3 25 | $6.6B | $36.2M | ||
| Q2 25 | $4.9B | $8.7M | ||
| Q1 25 | $1.4B | $17.6M | ||
| Q4 24 | $6.8B | $-4.7M | ||
| Q3 24 | $5.2B | $27.7M | ||
| Q2 24 | $2.0B | $8.9M | ||
| Q1 24 | $3.8B | $15.5M |
| Q4 25 | 29.4% | 1.2% | ||
| Q3 25 | 42.1% | 13.7% | ||
| Q2 25 | 31.7% | 3.3% | ||
| Q1 25 | 10.5% | 6.8% | ||
| Q4 24 | 44.7% | -1.8% | ||
| Q3 24 | 35.9% | 10.9% | ||
| Q2 24 | 14.0% | 3.4% | ||
| Q1 24 | 31.3% | 5.9% |
| Q4 25 | 2.0% | 0.4% | ||
| Q3 25 | 2.4% | 0.6% | ||
| Q2 25 | 1.7% | 0.7% | ||
| Q1 25 | 1.8% | 0.1% | ||
| Q4 24 | 1.9% | 0.2% | ||
| Q3 24 | 1.7% | 0.3% | ||
| Q2 24 | 1.7% | 0.3% | ||
| Q1 24 | 1.6% | 0.7% |
| Q4 25 | 2.87× | — | ||
| Q3 25 | 37.76× | 3.41× | ||
| Q2 25 | 5.49× | 2.04× | ||
| Q1 25 | 1.27× | 1.01× | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.49× | — | ||
| Q2 24 | 1.66× | — | ||
| Q1 24 | 2.95× | 86.50× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABBV
Segment breakdown not available.
EHAB
| Third Party Payor Medicare | $111.6M | 41% |
| Third Party Payor Medicare Advantage | $67.5M | 25% |
| Hospice Segment | $63.6M | 24% |
| Third Party Payor Managed Care | $24.9M | 9% |
| Third Party Payor Medicaid | $1.7M | 1% |
